Hayden is an assistant editor for The American Journal of Managed Care® (AJMC®) and joined AJMC® in 2021, where she produces written and video content covering multiple disease states.
She has a BA in journalism & media studies from Rutgers University. You can connect with Hayden on LinkedIn.
Jonathan Kentley Discusses Applications of AI in Dermatology
March 28th 2022Jonathan Kentley, MBBS, MSc, research fellow at Memorial Sloan Kettering Cancer Center, explains ways artificial intelligence (AI) is being used in dermatology, including smartphone applications, at the 2022 American Academy of Dermatology Annual Meeting.
Read More
Dr Bernice Kwong on GVHD: Empower Patients to Call on Doctors for Help
March 28th 2022Bernice Kwong, MD, clinical professor of dermatology, Stanford University, expands on her session about graft-versus-host disease diagnosis and management presented at the 2022 American Academy of Dermatology Annual Meeting, emphasizing the importance of the relationship between patients and doctors.
Read More
Dr David Rosmarin on Tailored Biologic Treatments, New Vitiligo Research
March 27th 2022David Rosmarin, MD, vice chair of research and education, Department of Dermatology, Tufts Medical Center, discusses best practices for choosing biologics, as well as his late-breaking findings on ruxolitinib cream for vitiligo at the 2022 American Academy of Dermatology (AAD) Annual Meeting.
Read More
Dr Robert Sidbury Summarizes Updated Atopic Dermatitis Guidelines at AAD 2022
March 27th 2022Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital, sat down to discuss comorbidities newly associated with atopic dermatitis at the 2022 American Academy of Dermatology Annual Meeting.
Read More
People With HIV More Likely to Develop Hypertension After Starting INSTI-Based ART vs NNRTI
March 26th 2022Adults living with HIV receiving integrase strand transfer inhibitor (INSTI)–based antiretroviral therapy (ART) had a 76% higher incidence of hypertension compared with adults receiving non-nucleoside reverse transcriptase inhibitors (NNRTIs).
Read More
Dr Art Papier on How Project IMPACT Aims to Reduce Racial Disparities in Dermatology
March 26th 2022The lack of racial representation in dermatology education prompted the launch of Project IMPACT, explained Art Papier, MD, dermatologist, CEO, VisualDx at the 2022 American Academy of Dermatology Annual Meeting.
Read More
Record High Pediatric Parainfluenza Virus Incidence in Finland
March 25th 2022Monthly parainfluenza virus incidence rates were nearly 6 times higher in September 2021 vs the second highest reported monthly incidence rates among children 4 years and younger in Finland in the last decade, following lifting of COVID-19–related restrictions.
Read More
Review Evaluates Outcome Domains for Self-management Interventions in Patients With IA
March 22nd 2022Variations between current core outcome sets and how trials are actually measuring self-management among patients with inflammatory arthritis (IA) show the need for further established outcome domains.
Read More
Dr Linda Stein Gold on What to Look Forward to at AAD 2022
March 21st 2022Linda Stein Gold, MD, director of dermatology clinical research at Henry Ford Health System, incoming vice president, American Academy of Dermatology (AAD), previews AAD 2022 and what she looks forward to both learning and teaching others.
Read More
NFID Board Members: We Need More Accessible, Less Expensive RSV Testing
March 19th 2022William Schaffner, MD, medical director at the National Foundation for Infectious Diseases (NFID), and Patsy Stinchfield, RN, MS, CPNP, president-elect of NFID, explain how COVID-19 testing developments have opened doors for developments in respiratory syncytial virus (RSV) testing.
Read More
Functional Impairment May Heighten Cardiometabolic Risk Among People Living With HIV
March 19th 2022Low functional status based on Duke Activity Status Instrument score was associated with higher cardiometabolic risk among individuals 45 years and older living with HIV, this new multinational cohort study found.
Read More
Genetic RA Associated With Inflammatory Bowel Disease, but Not Other Way Around
March 16th 2022The genetically-predicted risk of rheumatoid arthritis (RA) was positively associated with an increased risk of inflammatory bowel disease (IBD) and potentially with its main subtypes, ulcerative colitis and Crohn disease.
Read More
Mount Sinai Researchers Discuss Milestones in Understanding Genetic Variants
March 14th 2022Ron Do, PhD, associate professor, Charles Bronfman Institute for Personalized Medicine at Mount Sinai, and Iain Forrest, MD-PhD candidate in Dr Do’s lab, discuss their hopes for their findings and how genetic data are being used in health care.
Read More
Telemonitoring Just as Beneficial as In-Person Monitoring for Patients With RA Initiating DMARDs
March 12th 2022Using telemedicine to monitor patients with rheumatoid arthritis (RA) initiating disease-modifying antirheumatic drugs (DMARDs) was highly cost-effective and resulted in similar health outcomes compared with in-person monitoring.
Read More
Mount Sinai Researchers Explain Implications of Genetic Testing for Providers
March 12th 2022Ron Do, PhD, associate professor, Charles Bronfman Institute for Personalized Medicine at Mount Sinai, and Iain Forrest, MD-PhD candidate in Dr Do’s lab, explain their study's implications for providers and how age plays a role in genetic variant penetrance.
Read More
RA, But Not Related Autoimmunity, Associated With Increased CV Risk
March 5th 2022According to the study, rheumatoid arthritis (RA)-associated autoimmunity was not linked to increased cardiovascular (CV) event risk, suggesting systemic inflammation is likely required for precipitating CV events.
Read More
Mount Sinai Researchers Explain Biobanks Used in Clinical Variants Study
March 4th 2022Ron Do, PhD, associate professor, Charles Bronfman Institute for Personalized Medicine at the Icahn School of Medicine at Mount Sinai, and Iain Forrest, MD-PhD candidate in Dr Do’s lab, explain the differences between the biobanks used in their study on population-based penetrance of clinical variants.
Read More
HIV, HCV Testing Availability Stagnates Despite Growing Number of Substance Use Treatment Facilities
March 3rd 2022Although thousands of new substance use disorder treatment facilities that offer medication for opioid use disorder were opened between 2017 and 2020, the proportion of facilities that also offered HIV and hepatitis C virus (HCV) testing hardly changed.
Read More